<p>The newest advances in primary myelofibrosis (PMF) pathogenesis study, diagnostic and treatment approaches are presented in this article. The JAK-STAT signal pathway activation now recognized as main pathogenesis mechanism of PMF, it caused by JAK2, CALR, MPL genes mutations. Authors demonstrate their own data about epidemiology, clinical signs, diagnostic and treatment results of 315 PMF patients. The most frequent clinical symptoms are: anemia, leukocytosis, thrombocytosis, splenomegaly, constitutional symptoms. Diagnostic criteria, prognostic scales (including cytogenetic and molecular features) issues are reviewed. Intermediate-1 risk grade is in the most proportion of patients. The<br />recommended PMF treatment algorithm is listed....
The 2016 revision of the World Health Organization (WHO) classification of myeloproliferative neopla...
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical cour...
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal...
Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematologi...
Primary myelofibrosis (PMF) is a chronic clonal stem cell disease that causes an accumulation of mar...
Primary myelofibrosis (PMF) is a chronic myeloprolif-erative disorder associated with an average sur...
The classic BCR-ABL-negative myeloproliferative neoplasms (MPNs), a form of chronic malignant hemopa...
Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scot...
Myelofibrosis (MF) is a BCR/ABL-negative myeloproliferative neoplasm characterized by clonal myelopr...
Myelofibrosis is the accumulation of scar tissue in the bone marrow so that blood cells cannot devel...
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is ...
Primary myelofibrosis (PMF) is a disease from the group of Ph–negative myeloproliferative tumors, wh...
Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clini...
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinic...
The 2016 revision of the World Health Organization (WHO) classification of myeloproliferative neopla...
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical cour...
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal...
Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematologi...
Primary myelofibrosis (PMF) is a chronic clonal stem cell disease that causes an accumulation of mar...
Primary myelofibrosis (PMF) is a chronic myeloprolif-erative disorder associated with an average sur...
The classic BCR-ABL-negative myeloproliferative neoplasms (MPNs), a form of chronic malignant hemopa...
Raoul Tibes, James M Bogenberger, Ruben A MesaDivision of Hematology and Oncology, Mayo Clinic, Scot...
Myelofibrosis (MF) is a BCR/ABL-negative myeloproliferative neoplasm characterized by clonal myelopr...
Myelofibrosis is the accumulation of scar tissue in the bone marrow so that blood cells cannot devel...
Among classical BCR-ABL-negative myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) is ...
Primary myelofibrosis (PMF) is a disease from the group of Ph–negative myeloproliferative tumors, wh...
Currently available prognostic scoring systems in primary myelofibrosis (PMF) do not integrate clini...
Myelofibrosis (MF) is a myeloproliferative disorder that exhibits considerable biological and clinic...
The 2016 revision of the World Health Organization (WHO) classification of myeloproliferative neopla...
Introduction: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms a...
We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical cour...